Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
复制标题
DOI：
10.1200/jco.2014.55.7827
复制
发表时间：
2015-01-20
影响因子：
45.3
通讯作者：
Robidoux, Andre
中科院分区：
文献类型：
--
作者：
Boileau, Jean-Francois;Poirier, Brigitte;Robidoux, Andre
目的淋巴结阳性乳腺癌患者在新辅助化疗（NAC）后获得腋窝病理完全缓解的比例越来越高（> 30%）。如果前哨淋巴结（SN）活检（SNB）是准确的，在这种情况下，完成淋巴结清扫（CND）的发病率可以避免。患者和MethodsIn的前瞻性多中心SN FNAC研究，活检证实淋巴结阳性乳腺癌（T0-3，N1-2）的患者进行了SNB和CND。免疫组织化学（IHC）的使用是强制性的，任何大小的SN转移，包括孤立的肿瘤细胞（ypN 0 [i +]，≥ 90%和假阴性率（FNR））
PurposeAn increasing proportion of patients (> 30%) with node-positive breast cancer will obtain an axillary pathologic complete response after neoadjuvant chemotherapy (NAC). If sentinel node (SN) biopsy (SNB) is accurate in this setting, completion node dissection (CND) morbidity could be avoided.Patients and MethodsIn the prospective multicentric SN FNAC study, patients with biopsy-proven node-positive breast cancer (T0-3, N1-2) underwent both SNB and CND. Immunohistochemistry (IHC) use was mandatory, and SN metastases of any size, including isolated tumor cells (ypN0[i +], = 90% and false-negative rate (FNR)